长期服用非典型抗精神病药对患者体重指数、血浆瘦素和胰岛素低抗的影响

周凌云, 左笑丛, 张毕奎, 徐增益, 李静, 周亚男, 杨梦, 史雪莹

中国药学杂志 ›› 2012, Vol. 47 ›› Issue (12) : 997-1000.

中国药学杂志
中国药学杂志 ›› 2012, Vol. 47 ›› Issue (12) : 997-1000.
药物与临床

长期服用非典型抗精神病药对患者体重指数、血浆瘦素和胰岛素低抗的影响

  • 周凌云1a,b，左笑丛1a,b*，张毕奎1a,b，徐增益2，李静1a,b，周亚男1a,b，杨梦1a,b，史雪莹1a,b
作者信息 +

Effect of Long-Term Monotherapy of Atypical Antipsychotics on the Levels of Body Mass Index, Leptin Concentration and Insulin Resistance in Patients with Schizophrenia

  • ZHOU Ling-yun1a,b ，ZUO Xiao-cong1a,b*， ZHANG Bi-kui1a,b ，XU Zeng-yi2，LI Jing1a,b，ZHOU Ya-nan1a,b，SHI Xue-ying1a,b
Author information +
文章历史 +

摘要

目的 探讨长期服用氯氮平、奥氮平及利培酮对精神分裂症患者体重指数、血浆瘦素和胰岛素水平及胰岛素抵抗的影响及其之间的关系。方法 74例符合中国精神障碍分类与诊断标准第三版（CCMD-3）的精神分裂症长期单一用药患者与首发精神分裂症患者分为对照组（15例）、氯氮平组（27例）、利培酮组（19例）及奥氮平组（13例），测定并比较各组患者的血浆瘦素（leptin）、空腹胰岛素（FINS）水平及胰岛素抵抗指数（HOMA-IR）。结果 ①长期经氯氮平、奥氮平及利培酮治疗可致精神分裂症患者体重指数（BMI）显著增高（P<0.05），且氯氮平与奥氮平的作用强度大于利培酮；②长期经氯氮平、奥氮平及利培酮治疗可致精神分裂症患者血浆瘦素水平显著增高（P<0.05），影响程度：氯氮平> 奥氮平> 利培酮；③长期经氯氮平、奥氮平及利培酮治疗的精神分裂症患者空腹胰岛素及胰岛素抵抗指数水平较首发精神分裂症患者高，但组间无统计学差异；④相关性分析结果显示，精神分裂症患者体重指数与其血浆瘦素、空腹胰岛素水平及胰岛素抵抗指数均呈显著正相关（P<0.05）。结论 长期单一使用氯氮平、奥氮平及利培酮治疗，会导致精神分裂症患者体重增加，血浆瘦素、空腹胰岛素水平及胰岛素抵抗指数升高，且体重指数与血浆瘦素、空腹胰岛素水平及胰岛素抵抗指数均呈显著正相关，提示长期单一应用氯氮平、奥氮平及利培酮引起血浆瘦素和胰岛素抵抗指数增高是其所致代谢紊乱的重要原因之一。

Abstract

OBJECTIVE To compare the effects of clozapine，olanzapine and resperidone on the levels of body mass index (BMI)，leptin，fasting insulin concentration (FINS) and insulin resistance (IR) in inpatients with schizophrenia； to investigate the relationship between BMI，leptin，FINS and IR in subjects. METHODS Seventy-four Chinese inpatients with schizophrenia， treated with monotherapy of clozapine (n=27)，risperidone (n=19) and olanzapine (n=13) for at least one year or unmedicated (n=15)，were recruited；Levels of BMI，leptin，FINS and were measured, homeostasis model assessment of insulin resistance（HOMA-IR） were performed. RESULTS Significant difference in the mean levels of BMI was the found between four groups (P<0.05). In post hoc test， it was seen that clozapine and olanzapine-treated patients had higher levels of BMI than those in risperidone and control group； there was a significant difference in the level of leptin (P<0.05)， which was the highest in clozapine-treated patients； in the comparison of the mean values of FINS and HOMA-IR levels between four groups，there was no statistically significant difference. There was a positive correlation between BMI and leptin leves， FINs， and HOMA-IR (p<0.05). CONCLUSION Treatment with clozapine， olanzapine and risperidone is associated with abnormal glucose and lipid metabolism in inpatients with schizophrenia. The positive correlation between BMI and serum leptin， fasting serum insulin levels，HOMA-IR suggests that the increase of serum leptin and fasting serum insulin levels would be an important trait of metabolic syndrome related to monotherapy of treatment with clozapine，olanzapine and risperidone in inpatients with schizophrenia.

关键词

氯氮平 / 奥氮平 / 利培酮 / 精神分裂症 / 瘦素 / 胰岛素 / 胰岛素抵抗

Key words

clozapine / olanzapine / risperidone / schizophrenia / leptin / insulin / insulin resistance

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
周凌云, 左笑丛, 张毕奎, 徐增益, 李静, 周亚男, 杨梦, 史雪莹. 长期服用非典型抗精神病药对患者体重指数、血浆瘦素和胰岛素低抗的影响[J]. 中国药学杂志, 2012, 47(12): 997-1000
ZHOU Ling-Yun, ZUO Xiao-Cong, ZHANG Bi-Kui, XU Zeng-Yi, LI Jing, ZHOU Ya-Nan, YANG Meng, SHI Xue-Ying. Effect of Long-Term Monotherapy of Atypical Antipsychotics on the Levels of Body Mass Index, Leptin Concentration and Insulin Resistance in Patients with Schizophrenia[J]. Chinese Pharmaceutical Journal, 2012, 47(12): 997-1000
中图分类号： R969.3   

参考文献

[1] RIBOLSI M， KOCH G， MAGNI V， et al. Abnormal brain lateralization and connectivity in schizophrenia [J]. Rev Neurosci， 2009， 20(1)：61-70.[2] BALOUSH-KLEINMAN V， POYUROVSKY M， KOREN D， et al. Adherence to antipsychotic medication in schizophrenia patients [J]. Harefuah， 2002， 141(12)：1042-1049.[3] PERKINES D O. Adherence to antipsychotic medications [J]. J Clin Psychiatry， 1999， 60 (suppl 21) ：25-30.[4] CASEY D E， ZORN S H. The pharmacology of weight gain with antipsychotics [J]. J Clin Psychiatry， 2001， 62 ( suppl 7)： 4-10.[5] LIEBERMAN J A， TOLLEFS ON G， TOHENM， et al. Comparative efficacy and saftey of atipical and conventional antip sychotic drugs in first-episode psychosis： A randomized， double-blind trial of olanzapine versus haloperidol [J]. Am J Psychiatry， 2003， 160(8)： 1401-1403. [6] ZHANG Z J， YAO Z J， LIU W， et al. Effects of antip sychotics on fat deposition and changes in lep tin and insulin levels [J]. Br J Psychiatry， 2004， 184 (1)： 58-62.[7] KIM B J， SOHN J W， PARK C S， et al. Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine [J]. J Korean Med Sci， 2008， 23 (4)：685-690.[8] ATMACA M， KULOGLU M， TEZCAN E，et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics [J]. J Clin Psychiatry， 2003， 64(5)：598-604.[9] HENDERSON D C， CAGLIERO E， COPELAND P M， et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents： a frequently sampled intravenous glucose tolerance test and minimal model analysis [J]. Arch Gen Psychiatry， 2005， 62(1)：19-28.[10] AULAKHAULAK C S， HILL J K， YONEY H T， et al. Evidence of involvement of 5-HT1C and 5-HT2 receptors in the food intake suppressant effects of 1-(2，5-demethosy-4-iodophenyl)-2-aminopropane (DOI) [J]. Psychopharmacology (Berl)， 1992，109(4)：444-448.[11] WIRSHING D A， SPELLBERG B J， ERHART S M， et al. Novel antipsychotics and new onset diabetes[J]. Biol Psychiatry， 1998， 44(8)： 778-783.[12] OSSER D N， NAJARIAN D M， DUFRESNE R L， et al. Olanzapine increase weight and serum triglyceride levels [J]. J Clin Psychiatry， 1999， 60(11)： 767-770.[13] ZHOU Z L， LI X， XIE Y B， et al. Clinical pharmacokinetics of risperdal and its active metabolite in Chinese female patients with schizophrenia[J]. Chin Pham J (中国药学杂志)， 2008， 43(15)：1174-1176.[14] ZHANG Y， PROENCA R， MAFFEI M， et al. Positional cloning of the mouse obese gene and its human homologue [J]. Nature， 1994， 372(6505)： 425-432.[15] GRILARDI N， SKODA R C. The leptin receptor activates janus kinase and signals for proliferation in a factor-dependent cell line [J]. Mol Endocrinol， 1997， 11(4)： 393-399.[16] PELLEYMOUNTER M A， CULLEN M J， BAKER M B， et al. Effects of the obese gene product on body weight regulation in ob/ob mice [J]. Science， 1995， 269 (5223)： 540-543.[17] DONAHUE R P， PRINEAS R J， DONAHUE R D， et al. Is fasting leptin associated with insulin resistance among nondiabetic individuals? The Miami community health study [J]. Diabetes Care， 1999， 22(7)： 1092-1096.

基金

基金项目：湖南省自然科学基金面上项目（09JJ5035）；湖南省卫生厅资助课题（B2010-034）

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉